Flavonoids and their metabolites are well reported to modulate the activation/phosphorylation of various cellular kinases, such as ERK1/2 and JNK, although the mechanism by which they do so is unclear. In this study, we investigated the impact of flavanones on the activation of PI3K/Akt and ERK1/2 and determine whether this is mediated, in part, by the inhibition of phosphatases. Primary cortical neurons were exposed to physiological concentrations of hesperetin and the phosphorylation status of the kinases PI3K/Akt and ERK1/2 and the phosphatases PP2A and PTEN were assessed by immunoblotting after 30 min. Exposure to 100-300 nM hesperetin led to significant increases in the phosphorylation of ERK1/2 and Akt and significant decreases in PP2A levels and enzyme activity.
BACKGROUND
Accumulating evidence suggests that diet and lifestyle can play an important role in delaying the onset or halting the progression of age-related neurodegenerative diseases. A growing number of dietary intervention studies in humans and animals, in particular those using flavonoid-rich diets have been proposed to exert a multiplicity of neuroprotective actions within the brain, including a preservation of cognitive performance with ageing [1] [2] [3] , a delay in the onset of Alzheimer's disease [4, 5] and a reduction in the risk of developing Parkinson's disease [6, 7] . Their neuroprotective potential has been shown in both oxidative stress- [8, 9] and Aβ-induced-induced neuronal death models [10] . Evidence also supports the beneficial and neuromodulatory effects of flavonoid-rich blueberry and grape extracts, particularly in connection with age-related cognitive decline and Alzheimer's disease [11, 12] .
Flavonoids are well reported to cross the blood-brain-barrier (BBB) and have been detected in areas of the brain such as hippocampus, cerebral cortex, cerebellum and striatum [13] [14] [15] [16] , which are important for learning and memory formation and are also adversely affected by aging and neurodegenerative disorders [17, 18] . Hesperetin, a flavanone-type flavonoid, present as hesperidin (hesperetin 7-O-β-rutinoside) in the peel and pulp of a wide variety of citrus fruits and herbs [19] , is known to appear in the circulation as predominantly hesperetin glucuronide and sulfate conjugates [20, 21] , with studies reporting peak plasma concentrations ranging from 63 to 1500 nM [22, 23] . Nanomolar concentrations of flavonoids have previously been reported in the brain in animal models following oral ingestion [14, 15, 24] and hesperetin itself has been shown to have high apparent permeability (Papp) across the in vitro BBB model, mainly due to its lipophilic nature [25] and has been suggested to accumulate in the brain at nanomolar concentrations [26, 27] . Independent of this, a flavanone glucuronides may to cross the BBB using specific transporters, as has been previously described for morphine 6-glucuronide [28] . Furthermore, hydrolysis of the glucuronide moiety may also occur following release of beta-glucuronidase (EC 3.2.1.31), an enzyme present in high concentrations in the endoplasmic reticulum and in the lysosomal fraction of most cells, an event that may be exacerbated by localized inflammation. Collectively, these data indicate that flavanones might be capable of transversing the BBB, localizing within the brain and exerting direct neuroprotective and neuromodulatory actions.
The precise cellular mechanisms underlying the actions of flavonoids are still unknown but are thought to involve, in addition to their free radicals scavenging activity, the modulation of protein and lipid kinase signaling pathways [29, 30] . Previous investigations have highlighted that modulations of MAP kinase and PI3K/Akt signaling are central to mediating the cellular effects of flavonoids [29] [30] [31] .
For example, we previously reported that hesperetin was effective at preventing neuronal apoptosis via a mechanism involving the activation/phosphorylation of both Akt/protein kinase B and extracellular signal-regulated kinase 1 and 2 (ERK1/2) at physiological concentrations [32] .
Furthermore, the flavanone naringenin was able to inhibit p38 mitogen-activated protein kinase (MAPK) phosphorylation and downstream signal transducer and activator of transcription-1 (STAT-1) in LPS/IFN-gamma stimulated primary mixed glial cells [33] . In addition to MAPK signaling, recent evidence is also suggestive that flavonoids are able to modulate reversible phosphorylation through protein phosphatase activity, an important mechanism of signal transduction in eukaryotic cells [34] .
For example, the flavanol EGCG was previously reported to strongly inhibit protein phosphatase-1 (PP1) while showing a ten-fold lower activity toward the close homologue PP2A [35] . More recently, procyanidins were reported to negatively affect the activity of the PP1 and PRL phosphatases in regenerating livers [36] . These data not only indicate that flavonoids may exert cellular effects via direct interactions with MAPK and PI3K/Akt signaling proteins but may also be capable of cellular actions through protein phosphatases modulation. However, data related to the impact of physiologically relevant flavonoids on neuronal protein phosphatases remain to be investigated.
In this study we investigated the ability of the flavanone hesperetin to modulate neuronal signaling pathways at physiologically relevant concentrations, known in humans to be in the nanomolar to low micromolar range. We show that this dietary-derived compound has the capacity to activate both ERK and Akt signaling pathways, and that this kinase activation may be modulated through the inhibition of the protein phosphatase PP2A. In support of this, we show the molecular docking of hesperetin with the PP2A protein within the phosphatase active site of the catalytic unit. These results offer new avenues to the modulatory effect of flavonoids on neuronal signaling. MΩ.cm) passed through a purification system (Purite Ltd., Oxon, UK) was used for all purposes.
MATERIALS AND METHODS

Reagents
Neuronal culture and treatments
Primary cultures of mouse cortical neurons were prepared as described previously [32, 37] . Neurons were plated onto 6-well Nunc multi-well plates that had been pre-coated overnight with poly-Lornithine and then with 10% heat inactivated fetal bovine serum (Gibco-BRL, Paisley, UK) for 2h.
Following removal of the final coating solution cells were plated (10 6 /ml) in a serum-free medium composed of a mixture of DMEM and F-12 nutrient (1:1 v/v) supplemented with glucose (33 mM), glutamine (2 mM), sodium bicarbonate (6.5 mM), HEPES (pH 7.4, 5 mM), streptomycin (100 µg/ml) and penicillin (60 UI/ml) (all Gibco-BRL). A mixture of hormones and salts composed of insulin (25 µg/ml), transferrin (100 µg/ml), putrescine (60 µg/ml), progesterone (20 nM) and sodium selenate (30 nM) (all from Sigma) was also added to the culture medium. Cells were cultured at 37°C in a humidified atmosphere of 95% air and 5% CO2 and after 5 to 7 days the vast majority of cells were neuronal (> 98%) with < 2% astrocytes as determined by -tubulin and GFAP immunocytochemistry respectively [38] . To investigate the effect of the flavanone on signaling pathways, neurons were incubated for 30 minutes with hesperetin (0-0.3 µM). This time point was selected based on our previous investigation [32] .
Phosphatase assay
Phosphatase activity of mouse cortical neuronal cells was quantitated using the DuoSet® IC Active PP2A assay kits (R&D Systems, DYC3309) by measuring the dephosphorylation of a synthetic phospho-peptide, DLDVPIPGRFDRRVS(PO3)VAAE by active phosphatase PP2A. Briefly, cortical neurons plated in 6-cm Petri dishes were rinsed twice in TBS and lysed in the phosphatase buffer (50 mM HEPES, 0.5% NP-40 (pH 7.5), 0.1 mM EGTA, 0.1 mM EDTA, 120 mM NaCl) containing protease inhibitors (25 µg/mL Leupeptin, 25 µg/mL Pepstatin, 2 µg/mL Aprotinin, 1 mM PMSF). Proteins were extracted on ice with periodic vortexing for 15 min. Cells were thoroughly solubilised by passing the lysates through a 19-gauge needle 20 times and cleared by centrifugation at 12,000 x g for 5 min at 4 °C. Diluted supernatants were then incubated with 200 μM of synthetic phosphopeptide DLDVPIPGRFDRRVS(PO3)VAAE on a rocking platform at 30 rpm for 30 minutes at 37° C in a buffer consisting of 50 mM Tris (pH 7.5), 10 mM MgCl2, 0.02% Brij-35, 1 mg/mL BSA without or with 20 nM okadaic acid. Following incubation, Malachite Green was added to the mixture and incubated for 20 min at room temperature to allow color development. Absorbance was measured at 620 nm using the Genios Tecan microplate reader. Phosphate released was determined by comparing absorbance to a standard phosphate curve. To calculate PP2A specific activity, total PP2A levels were also quantified using the DuoSet® IC Total PP2A assay kits (R&D Systems, DYC1653).
Immunoblotting
Following exposures, neurons were washed with ice-cold PBS (+ EGTA 200 mM) and lysed on ice using Tris (50mM), Triton X-100 (0.1%), NaCl (150mM) and EGTA/EDTA (2 mM), containing mammalian protease inhibitor cocktail (1:100 dilution), sodium pyrophosphate (1 mM), PMSF (10 mg/ml), sodium vanadate (1 mM) and sodium fluoride (50 mM 
In Silico Docking
Docking calculations were conducted with SwissDock, a protein-small molecule docking web service [39] . SwissDock is based on the docking software EADock DSS, whose algorithm consists of the following steps: i) many binding modes are generated either in a box (local docking) or in the vicinity of all target cavities (blind docking); ii) simultaneously, their CHARMM energies are estimated on a grid; iii) the binding modes with the most favorable energies are evaluated with FACTS, and clustered; iv) the most favorable clusters can be visualized online and downloaded on a personal computer (http://swissdock.vital-it.ch/). UCSF Chimera (a visualization system for exploratory research and analysis) was used for molecular structure viewing [40] . The crystal structure was obtained from the PDB with the accession code 2NYM_C [41] . Hesperetin 3D structure was obtained by the ZINC 15 Database [42, 43] (code 39092).
Statistical analysis
All results are expressed as means ± SEM of three separate experiments unless otherwise stated.
The statistical evaluation of the results was performed by one-way analysis of variance (ANOVA)
followed by a Bonferroni's multiple comparison test using GraphPad Prism version 5 (GraphPad Software, San Diego, CA, USA). Significance was defined as p < 0.05.
RESULTS
Hesperetin stimulates Akt and ERK phosphorylation in cortical neurons
To investigate the phosphorylation state of ERK1/2 and Akt/PKB, phospho-specific antibodies were employed that recognize the dually phosphorylated motif pTEpY within activated ERK1/2, and the 
Hesperetin decreases PP2A activity in cortical neurons
Since phosphatases can modulate the activities of several kinases in vitro and in vivo, such as ERK suggesting specific inhibition of the enzyme. These results are consistent with previous reports demonstrating specific inhibition of PP2A activity by OA [45] . Next, we determined PP2A specific activity by calculating the ratio of phosphate released per minute to total PP2A protein. Although there was a loss of total PP2A protein with hesperetin treatment (data not shown), a significant decrease in the specific activity of the enzyme was observed [F (2, 6) = 20.17; P = 0.0022] ( Figure 3B ). These data correlate well with the relative total amounts of PP2A detected by western blot, showing a significant decrease in PP2A immunoreactive bands.
Molecular docking of Hesperetin on PP2A
The PP2A core enzyme consists of a 36 kDa catalytic subunit, or C subunit, and a 65 kDa scaffolding protein, known as the A or PR65 subunit [46] . Previous investigations looking into OA binding to PP2A revealed a binding pocket located in the active site of PP2A catalytic unit. On one end of the binding pocket, four amino acids in the catalytic subunit of PP2A, Gln122, Ile123, His191, and Trp200, form a hydrophobic cage, which accommodates the hydrophobic end of OA. On the other end of the binding pocket, Leu243, Tyr265, Cys266, Arg268, and Cys269 make multiple van der Waals interactions with the hydrophobic portion of the bound toxin [47] .
In order to gain insight into the putative binding mode of hesperetin with PP2A catalytic subunit, it was docked with a crystallographic structure of human PP2A using SwissDock. The crystallographic structure was obtained from the Protein Data Bank (PDB), accession code 2NYM_C [41] . The docking model predicted by SwissDock indicates that hesperetin is able to fit into the active site of PP2A (Fig 4A and B) . In particular, we observed interaction within the hydrophobic cage at two main sites (site A and B) representing the overall binding pocket of the catalytic unit. In particular, hesperetin interacts with residues of site A (Pro190) and B (Leu243 and Hsd252; Fig 4C) where it creates hydrogen bonds. In addition, hesperetin also established hydrophobic links with the ligand rings through interaction with the site B surface residues Val244, Asn249 and Trp250 (Fig 4D) .
Predicted binding energies for hesperetin-PP2A complex are summarized in Table 1 .
DISCUSSION
Flavonoids have been proposed to exert beneficial effects in a multitude of diseases, including cancer, cardiovascular disease and neurodegenerative disorders [48] [49] [50] . signaling pathways resulting in the protection of neurons from apoptosis [52] . Our current data indicate that exposure of primary cortical neurons to low nanomolar concentrations of hesperetin resulted in a significant increase in the phosphorylation of ERK1/2 and Akt at Ser473. These data are in agreement with our previous findings demonstrating that hesperetin was effective at modulating both Akt/protein kinase B and extracellular signal-regulated kinase 1 and 2 (ERK1/2) in neurons [24] .
Although the uptake and distribution of dietary flavonoids within the brain is well documented, at least in animal studies, the concentration within specific neuronal tissues remains uncertain. Discrepancies mainly stem from the fact that studies reporting flavonoid brain uptake and concentrations often disregard residual blood as a potential confounder. However, data deriving from studies using neuronal tissue extracted from perfused animals suggests that flavonoids may localise in the brain at levels up to 1 nmol/g tissue [53] and in a non regio-specificic manner [54, 55] . Hesperetin itself has been shown to have high apparent permeability (Papp) across the in vitro BBB model, mainly due to its lipophilic nature [25] and was observed in the brain tissue at nanomolar concentrations [26, 27] .
The concentrations used in our study reflect those observed in the brain in vivo. This is very important, as flavonoids have been shown to act as pro-apoptotic stimuli at higher concentrations.
Indeed, we have previously shown that quercetin and its metabolites 3'-O-methyl quercetin and 4'-Omethyl quercetin inhibit protein kinase B/Akt (Akt) and ERK1/2 phosphorylation, an action underlying their pro-apoptotic action towards cortical neurons [56] .
Reversible phosphorylation is a very important mechanism of signal transduction and is mediated by a series of kinases and phosphatases [34] . Amongst phosphatases, protein phosphatase 2A (PP2A) is one of the most conserved proteins and together with PP1, is responsible for up to 90% of all serine/threonine activity in a cell [57] . As a phosphatase, PP2A functions in many of the major cell signaling pathways including those that regulate the cell cycle, cell metabolism, cell migration and cell survival [58] . Numerous observations in vitro suggest that PP2A plays a major role in the downregulation of the ERK and Akt/PKB pathways, and that PP2A may be active at several levels of the signaling cascade [44] . Our results show that concomitant to ERK and Akt activation/phosphorylation, PP2A was significantly decreased by hesperetin treatment.
The balanced and highly dynamic interplay between kinases and phosphatases is critical for the control of intracellular signalling and consequently aberrant regulation of either protein kinases and/or phosphatases may play a causative role in diseases such as diabetes and neurological disorders [59] .
As such both kinases and phosphatases may act as therapeutic in the aetiology of many diseases [60] [61] [62] [63] [64] [65] . With respect to phosphatases, their regulation and/or activation status may lead to a variety of outcomes. For example, protein tyrosine phosphatase (PTP) 1B has been reported to negatively regulate insulin and leptin signalling making it a prime target for enhancing insulin sensitivity and controlling body mass [62] . In support of this, PTP1B-deficient mice show an enhanced insulin sensitivity, improved glycemic control, and resistance to high fat diet induced obesity [66, 67] . As In addition to their role in modulating key intracellular signalling pathways involved in various aspects of physiology, phosphatases are thought to play a key role in neuronal function, including synaptic plasticity, apoptotic cell death [69] and neuroinflammation [70] . PP2A is speculated to be a potential biological target for the drug treatment of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease [69, 71] . Here, they may contribute to the abnormal phosphorylation of proteins, such as tau in the neurofibrillary tangles of Alzheimer's disease [72] or α-synuclein in the Lewy bodies of PD [73] . The abnormal hyperphosphorylation of such proteins is generally believed to lead to their mis-folding and aggregation [74] . Thus, effective inhibition of phosphatases such as PP2A may attenuate the progression of these neurodegenerative diseases. However, it remains unclear whether activation or inhibition of such phosphatases would be most therapeutic and also whether their inhibition may promote carcinogenesis. While it seems counterintuitive to inhibit a tumour suppressor such as PP2A, inhibitors such as LB-100 are known to sensitize tumours to chemotherapy and radiotherapy by blocking the removal of phosphate groups from proteins essential for cell cycle progression. Thus, when used with radio-or chemotherapy treatments, malignant cells will progress through the cell cycle without having their damaged DNA repaired thus shunting them to undergo tumour cell apoptosis. With respect to the ability of flavanones to inhibit other phosphatases, it is known that the function of protein-tyrosine phosphatases depends on a critical cysteine residue at the catalytic site, which forms a thiol-phosphate intermediate during catalysis [75, 76] . Interaction with this thiol residue may therefore disrupt enzyme active. Whilst it is currently unknown whether flavanones may interact within this essential cysteine, under cellular conditions some flavonoids are capable of autoxidising and covalently binding to cellular thiols [77] .
In summary, our findings suggest that observations relating to increases in kinases following exposure to flavonoids, including flavanones such as hesperetin may result in part due to the inhibition of phosphatases such as PP2A. Although the precise mechanism is yet to be established, and importantly the activity of phase II conjugated metabolites, such as glucuronides and sulphates, inhibition of phosphatases by flavanone aglycones may represent one mechanism by which flavonoids influence physiological function at the cellular level.
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